Cargando…
(68)Gallium- and (90)Yttrium-/(177)Lutetium: “theranostic twins” for diagnosis and treatment of NETs
Abundant expression of somatostatin receptors (SSTR) is frequently identified in differentiated neuroendocrine tumors and may serve as potential target for diagnostic imaging and treatment. This article discusses the “theranostic approach” of SSTR-targeting compounds including an overview of its rol...
Autores principales: | Werner, Rudolf A., Bluemel, Christina, Allen-Auerbach, Martin S., Higuchi, Takahiro, Herrmann, Ken |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306729/ https://www.ncbi.nlm.nih.gov/pubmed/25139472 http://dx.doi.org/10.1007/s12149-014-0898-6 |
Ejemplares similares
-
Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep
por: Baur, Benjamin, et al.
Publicado: (2014) -
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022) -
Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms
por: Saracyn, Marek, et al.
Publicado: (2022) -
Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study
por: Bober, Barbara, et al.
Publicado: (2022) -
Theranostic Imaging of Yttrium-90
por: Wright, Chadwick L., et al.
Publicado: (2015)